141790-23-0
141790-23-0 結(jié)構(gòu)式
基本信息
中文別名
福齊夫定替酯 英文別名
Fozivudinefozivudine tidoxil
(2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl (2-decoxy-3-dodecylsulfanylpropyl) hydrogen phosphate
常見(jiàn)問(wèn)題列表
生物活性
Fozivudine tidoxil (BM-211290) 是具有口服活性的硫醚脂質(zhì)-齊多夫定 (lipid-zidovudine) 偶聯(lián)物，具有抗 HIV 活性的。Fozivudine tidoxil 是 NRTI 家族成員，在細(xì)胞內(nèi)病毒復(fù)制過(guò)程中被摻入到新合成的 DNA 鏈中，并且不可逆地結(jié)合病毒 RT，從而破壞病毒的逆轉(zhuǎn)錄。靶點(diǎn)
|
HIV
|
體外研究
Fozivudine tidoxil (BM-211290) is a member of the nucleoside analogue reverse transcriptase inhibitor (NRTI) family.
體內(nèi)研究
Fozivudine tidoxil (BM-211290; 45 mg/kg; PO; twice daily; one day before FIV challenge for a total of six weeks) is effective at lowering plasma- and cell-associated viremia at two weeks post-FIV infection.
| Animal Model: | Specific pathogen-free cats at 6 months of age |
| Dosage: | 45 mg/kg |
| Administration: | PO; twice daily; one day before FIV challenge for a total of six weeks |
| Result: | Effective at lowering plasma- and cell-associated viremia at two weeks post-feline immunodeficiency virus (FIV) infection with a trend toward lower plasma- and cell- associated viremia at four and six weeks post-infection (PI). |